Assessment of the most impactful combination of factors associated with nocturia and to define nocturnal polyuria by multivariate modelling by Olesen, Tine et al.
                          Olesen, T., Paul, J., Gramme, P., Drake, M. J., Vande Walle, J., &
Everaert, K. (2020). Assessment of the most impactful combination of
factors associated with nocturia and to define nocturnal polyuria by
multivariate modelling. Journal of Clinical Medicine, 9(7), [2262].
https://doi.org/10.3390/jcm9072262
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.3390/jcm9072262
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via MDPI at
https://www.mdpi.com/2077-0383/9/7/2262. Please refer to any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the





Assessment of the Most Impactful Combination of
Factors Associated with Nocturia and to Define
Nocturnal Polyuria by Multivariate Modelling
Tine Olesen 1,* , Jerome Paul 2, Pierre Gramme 2, Marcus J. Drake 3 , Johan Vandewalle 4 and
Karel Everaert 1
1 Urology Department, Ghent University Hospital, 9000 Ghent, Belgium; Karel.Everaert@uzgent.be
2 DNAlytics, 1348 Louvain-la-Neuve, Belgium; jerome.paul@dnalytics.com (J.P.); pgramme@gmail.com (P.G.)
3 Bristol Urological Institute, University of Bristol, Bristol BS105NB, UK; marcus.drake@nbt.nhs.uk
4 Department of Pediatric Nephrology, Safepedrug, University Hospital Ghent, 9000 Ghent, Belgium;
johan.vandewalle@uzgent.be
* Correspondence: tinekoldolesen@gmail.com; Fax: +49-15155385918
Received: 6 June 2020; Accepted: 6 July 2020; Published: 16 July 2020


Abstract: Background: Nocturia is common and associated with multiple disease states.
Many potential mechanisms have been proposed for nocturia, which also remains challenging
to manage. Purpose: To use multivariate analysis to determine which combinations of factors can
accurately discriminate clinically significant nocturia in patients to facilitate clinical management and
treatment decisions. Patients and methods: Data analysis was based on frequency volume charts
from three randomized controlled trials. There were 1479 patients included, of which 215 patients
had no/mild nocturia and 1264 had clinically significant nocturia with at least two voids per night.
Factors studied that may influence nocturia were demographics, sleep duration, functional bladder
capacity, 24 h urine volume and literature-suggested definitions of nocturnal polyuria. We used
univariate analysis and cross-validated multivariate modelling to assess association between factors
and nocturia status, redundancy between factors and whether the combined use of factors could
explain patients′ nocturia status. Results: The multivariate analyses showed that the most useful
definitions of nocturia are ’Nocturia Index’ (NI) and ‘Nocturnal Urine Production per hour’ (NUPh)
in combination with functional bladder capacity and sleep duration. Published definitions providing
binary nocturnal polyuria outcomes had lower performance than continuous indices. These analyses
also showed that NI was not specific to nocturnal polyuria as it also captured nocturia due to low
functional bladder capacity. By contrast, NUPh was demonstrated to be specific to nocturnal polyuria.
Conclusion: NUPh has previously been shown among elderly males to be essential in nocturia and a
very valid measure of nocturnal polyuria. However, the current, large and independent dataset now
confirms that it can be applied in an adult population with a complaint of nocturia covering both
males and females.
Keywords: nocturia; nocturnal polyuria definition; multivariate modelling; combination of factors
impacting nocturia
1. Introduction
Nocturia, or waking up at night to void, is common. Two or more voids per night lead to impaired
sleep health and lower health-related quality of life [1]. Thereby, the occurrence of two or more
voids per night represents the threshold above which nocturia shifts from being perceived as a minor
inconvenience to a bothersome and clinically meaningful condition, also resulting in an economic
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burden for society [2]. Nocturia is associated with multiple disease states [3]. Factors underlying
nocturia may differ between individual patients but may also coexist within one patient.
In essence, the nocturia symptom is a result of the imbalance between functional bladder storage
capacity (FBC) and urine production. Impaired FBC leads to small voided volumes and can be caused
by underlying conditions, such as idiopathic/neurogenic detrusor overactivity and bladder outlet
obstruction due to benign prostate enlargement (BPE). Treatments to improve FBC include beta-3
adrenergic agonists or anticholinergics in patients with detrusor overactivity and overactive bladder
(OAB) symptoms, and α-blockers or 5α-reductase inhibitors in cases of BPE. The evidence for the
effectiveness of these treatments in nocturia is limited [4–7].
Increased urinary output can occur overnight only or during a 24 h period. It can develop for many
different reasons including lifestyle factors, heart failure, diabetes insipidus or mellitus, decreased
vasopressin levels, venous insufficiency, or obstructive sleep apnea [8]. Interventions directed to
reduce nocturnal urinary output include evening fluid restriction, leg elevation during daytime, timed
diuretics, and antidiuretic treatment with desmopressin [9,10]. In fact, one study has shown that
nocturnal polyuria (NP) was the most common contributor to nocturia [11].
There are different definitions of NP, all with limited evidence and varying specificity and sensitivity.
The International Continence Society (ICS) issued, in 2002, a definition of NP [12] and the recent
terminology update in 2019 also mentions the NP definition from ICS [13]. This definition—as well as
other definitions—were later criticized due to their lack of accuracy in identifying nightly excess of
urine resulting in the symptom of clinically significant nocturia [14].
This suggests multiple causes of nocturia in co-existence, and therefore, the pathophysiology of
nocturia should not be reduced to one of a handful of basic mechanisms. Because of the multifactorial
etiology, we hypothesized that statistical multivariate modeling [15] may be relevant as a tool to
explain clinically significant nocturia. We aimed to determine which factors were accurately associated
with nocturia. We also tested the ability of proposed definitions of NP, both as continuous and
binary variables, to explain nocturia. Finally, we evaluated NP definitions as associated with nightly
excess of urine, with the overall aim of facilitating clinical management and optimizing individual
treatment decisions.
2. Materials and Methods
2.1. Study Design and Protocol
This is a post-hoc analysis based on screening data from three prospective phase 3, randomized
controlled trials (000085/NCT01729819, CS40/NCT01223937, CS41/NCT01262456, see ClinicalTrials.gov)
conducted to test the efficacy/safety of desmopressin in 2575 patients in Europe and North America
(Table 1). As these analyses were based on screening data, patients had received no trial interventions
prior to data collection. The main inclusion criteria for the screening phase was a complaint of nocturia
in patients above 18 years of age. Data collection was based on 24 h frequency volume charts (FVC),
collected for 72 h.
Table 1. Patients included in the studies.
Excluded from the Analysis/Trial: 000085 CS40 CS41 Total
Total no. of patients 913 649 1013 2575
Exclusion criteria 200 81 110 391
Race 8 7 20 35
Missing Frequency Volume Chart 114 189 367 670
Remaining in the analysis 591 372 516 1479
For the current study, we excluded patients (n = 391) with comorbidities outside the functional
urology therapy area which may contribute to nocturia but which should be addressed by specialists
in the relevant field before treating nocturia specifically [16]. This included conditions such as
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uncontrolled hypertension (n = 49), uncontrolled diabetes mellitus (n = 37), severe urgency and
incontinence (n = 82), history of urological malignancies during the past 5 years (n = 9), polydipsia
(n = 71), cardiac failure (n = 3), sleep apnea (n = 24), hepatic and biliary diseases (n = 43), current
bladder stone or infection (n = 17), neurogenic detrusor overactivity (n = 2), alcohol and substance
abuse (n = 4), renal impairment (n = 14). We also excluded those who withdrew consent (n = 37) and
those with missing FVC (n = 670). Finally, those of American Indian and Asian of Hawaii or Pacific
Island ethnicity (n = 35) were excluded as there were no matched controls in the no/mild nocturia)
patient group for comparison. Our final analysis included 1479 patients of whom 215 had no/mild
nocturia (less than 2 voids) and 1264 had clinically significant nocturia (at least 2 voids per night).
Factors proposed to influence nocturia were divided into three categories:




Body mass index (BMI)
(2) Factors pertaining to fluid intake and urine output in relation to volume and time. These were
denominated intake/output factors, and included:
- Functional bladder capacity (estimated based on ‘maximum voided volume’)
- 24 h urine volume
- Sleep duration
- Liquid intake within 1 h before going to bed
(3) NP definitions already proposed in the literature. These were tested as either continuous or
binary threshold variables (in total, 12 definitions):
- NUPh (nocturnal urine production per hour): ratio of nocturnal voided volume * to
night duration
- NUPh > 54 mL/h, NUPh > 78 mL/h and NUPh > 90 mL/h [17]
- NUPw (nocturnal urine production per weight): ratio of nocturnal voided volume * to
body weight
- NUPw > 10 mL/kg [18]
- NPI (nocturnal polyuria index): ratio of nocturnal voided volume to 24 h total voided volume
- Age > 65 and NPI > 0.33 or Age > 20 and NPI > 0.2 [19]
- NI (nocturia index): ratio of nocturnal voided volume to functional bladder capacity (i.e.,
max voided volume)
- NI > 1.5 or NI > 1 [20]
- NPIh: ratio of NUPh by DUPh (daytime urine production per h per 24 h)
* Including first morning void.
These definitions were originally developed using a diverse set of outcome measures and based on
study cohorts with limited sample sizes representing a subset of the general population. The definitions
were found to be inaccurate with either high sensitivity but low specificity or vice versa when they
were evaluated in a different or larger population. There were several papers that suggested major
covariates exerted an important influence on the precision of the definitions. Currently, there is no
optimal definition of nocturnal polyuria that offers accurate diagnostic value when tested in a general
population [21–31].
Table 2 below shows the patients’ baseline characteristics. Patients had a median age of 59 years
(interquartile range (IQR): 48–68) with 65% being females. The median number of nocturnal voids was
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for the no/ mild nocturia patients 1.5 (IQR: 1.0–1.7) and for the clinically significant nocturia 2.7 (IQR:
2.2–3.3). The NP definitions were applied to the population. In the table, “True” means congruence
with the definition of NP and “False” means no congruence with the NP definition. For comparison,
in the group of 670 patients that were excluded due to no FVC data, the median age was 66 years (IQR:
53–72) and there was a higher proportion of males (54.78%), but ethnicity and BMI were similar to the
group included in the study (24.78% were African American; BMI: 28.60 (25.45–33.15)).










AGE (y) 56.00 (47.50–66.50) 215 60 (48–68) 1264
Gender at Birth Female (76.28%) 164 (63.21%) 799
Male (23.72%) 51 (36.79%) 465
Race AfricanAmerican (30.7%) 66 (23.66%) 299
White (69.3%) 149 (76.34%) 965
BMI 29.00 (25.40–33.55) 215 29.20 (26.00–34.10) 1264
Nocturnal Void (#) 1.50 (1.00–1.67) 215 2.67 (2.33–3.33) 1264
Max Voided Volume/Functional
Bladder Capacity (mL) 355.00 (281.25–500.00) 214 300 (200–420) 1259
Volume 24 h (mL) 1300.00 (920.62–1771.58) 186 1390.00 (966.67–1875.83) 1176
NUPh (mL/h) 53.50 (37.19–77.97) 206 65.18 (43.50–90.96) 1226
NUPh > 90 TRUE (31 (15.0%)) (314 (25.6%)) (765 (62.4%))
FALSE (175 (85.0%)) (912 (74.4%))
NUPh > 78 TRUE (52 (25.2%)) (449 (36.6%))
FALSE (154 (74.8%)) (777 (63.4%))
NUPh > 54 TRUE (102 (49.5%)) (765 (62.4%))
FALSE (175 (85.0%)) (461 (37.6%)) (912 (74.4%))
NUPw (mL/kg) 5.40 (3.45–7.59) 214 6.82 (4.47–9.65) 1241
NUPw > 10 TRUE (26 (12.1%)) (276 (22.2%))
FALSE (188 (87.9%)) (965 (77.8%))
NPI 0.34 (0.28–0.43) 186 0.41 (0.34–0.50) 1176
NPI_binary TRUE (170 (91.4%)) (1150 (97.7%))
FALSE (16 (8.6%)) (27 (2.3%))
NPIh 0.04 ((0.03–0.05) 185 0.05 (0.04–0.06) 1155
NI 1.24 (0.94–1.45) 214 1.87 (1.47–2.35) 1241
NI > 1.5 TRUE (49 (22.9%)) (910 (73.3%))
FALSE (165 (77.1%)) (331 (26.7%))
NI > 1 TRUE (146 (68.2%)) (1153 (92.9%))
FALSE (68 (31.8%)) (88 (7.1%))
Sleep Duration (h) 8.24 (7.52–8.98) 206 8.89 (8.15–9.67) 1247
Intake_Night (L) 0.00 (0.00–3.33) 85 0.00 (0.00–2.92) 803
FVC: Frequency volume chart; NUPh: nocturnal urine production per hour; NUPw: nocturnal urine production per
weight; NPI: nocturnal polyuria index; NI: nocturia index; BMI: body mass index; # number.
2.2. Statistical Analysis
‘R’ software was used for all analyses (https://www.r-project.org/).
Descriptive statistical analysis was used to assess whether different variables could discriminate
clinically significant nocturia from no/mild nocturia. Non-parametric Wilcoxon rank-sum tests were
used for continuous variables and Fisher′s exact tests were applied on categorical variables. p-values
were corrected for multiple testing using Benjamini–Hochberg procedure [32].
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We used cross-validated predictive model learning to assess whether multivariate combinations
of the different factors could accurately discriminate clinically significant nocturia from no/mild
nocturia [14]. Predictive models were repeatedly trained from a random sub-sample of the dataset and
performance was assessed on a distinctly separate data set from the remaining sample (to evaluate
its generalization capability). The discrimination was reported as mean Area Under the Receiver
Operating Characteristic Curve (AUC) with 95% confidence interval [32]. Candidate predictive
models were: Random Forest (RF, a non-linear, potentially complex model) and Regularized Logistic
Regression (LR, a simple and robust linear model).
A total of 26 candidate signatures (i.e., lists of predictor variables) were evaluated:
Direct factors:
- 12 signatures, each including one NP definition and all four intake/output factors
- One signature with the four intake/output factors, excluding NP definitions
All factors (direct and indirect):
- 12 signatures, each including one NP definition, all four intake/output factors, and all four
demographic factors
- One signature with the four intake/output factors and four demographic factors, excluding
NP definitions
Finally, we determined the correlation between NP and the predicted probability of clinically
significant nocturia, and analyzed the models′ weights to determine the role of NP in the best linear
associated model.
2.3. Ethics Approval and Consent to Participate
All participants gave written informed consent at the time of recruitment, and the project was
approved by the local IRB/Ethics Committee.
3. Results
In univariate analysis, FBC, sleep duration, all proposed definitions of NP using both continuous
and binary variables, gender at birth and race discriminated no/mild nocturia from clinically significant
nocturia patients. Fewer variables tended to be identified as significant in analyses based on a per
study basis. Details are provided in Table S1.
Nocturia models based on intake/output factors and NP definitions discriminated clinically
significant nocturia from no/mild nocturia well, as shown in Figure 1.
The model based on NI and additional intake/output factors had highest discrimination capability,
followed by models based on NUP-indices, finally followed by NPI-indices. Our analysis also showed
that models using NI or NUPh as a continuous NP definition combined with intake/output factors
discriminate well (AUC: 82–84%, 77–80%, respectively). All models using binary definitions of NP
had lower accuracy compared to those based on the corresponding continuous indices. Still, NI > 1.5
had high discriminatory accuracy (AUC:77–80%). Notably, the nocturia model using NPI as a binary
definition combined with intake/output factors had lower association power than any other model
including models that did not include any definition of NP. In general, nocturia models that added the
demographic factors did not further improve the accuracy as other factors mediated these associations.
The association power varied between studies. Although the study cohorts of CS40 and CS41
were based on identical protocols, they differed in that CS40 was performed in women and CS41 in
men; CS40 provided higher discrimination capabilities.
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Figure 1. Pooled and per stud analysis of nocturia versus non-nocturia discrimination factors.
Each curve reports the AUC (y-axis) for different signatures (x-axis) and two different classifiers
(two colors). AUC: Area under the curve; bin: binary; classif: classification; gt: greater than; gte: greater
than or equal to; LR: logistic regression; NI: nocturia index; NUPh: nocturnal urine production per h;
NUPw: nocturnal urine production per weight; NPI: nocturnal polyuria index; RF: random forest.
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The continuous definitions NI and NUPh discriminated the patients with clinically significant
nocturia from those with no/mild nocturia best. To investigate further which definition was most
strongly associated with excess nightly urine production, we calculated the predicted probability of
nocturia as a function of NI or NUPh, based on multivariate logistic regression (Figure 2).
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Figure 2. Correlation b tween nocturia and NI (left) and NUPh (right). NI: nocturia index; NUPh:
nocturnal uri e production per h.
The figure for NI as a function of nocturia was perfectly shaped to identify nocturia, with a
correlation of 96%, which explained why no other intake/output factors were required to identify
nocturia. Using a tentative NI cut-off of 1.5 showed a 50% probability of clinically significant nocturia,
and NI values above 1.5 increased the probability of having clinically significant nocturia. Therefore,
the NI parameter identified the risk of nocturia as a bothersome symptom but was not specific to an
excess of nightly urine production. Applying the same principle to NUPh showed that the correlation
as only 37% when using NUPh to identify nocturia. However, when NUPh was combined with
bladder capacity and sleep duration, the AUC was 80%, i.e., similar to the AUC for NI alone.
4. Discussion
The management of nocturia patients is challenging. The etiology is of mixed origin and there is
little available evidence about the effects of possible combinations of treatment modalities. However,
the reported multivariate analyses provide insights into each factor’s capability to discriminate patients
with clinically significant nocturia from those with no/mild nocturia. It, therefore, helps the treating
physician to characterize each etiological factor, thereby facilitating treatment choices that can maximize
the benefit for patients.
The recognized definitions of NP used today are binary, i.e., a fixed threshold for having NP or not.
Our results strongly suggest that the binary approach to diagnose NP is suboptimal. This is consistent
with the recognition that nocturia is a multifactorial symptom where each factor contributes with a
different magnitude of bother. The currently used binary definitions of NP all had lower discrimination
power than the continuous versions of the definitions to identify clinically significant nocturia. Notably,
NPI, which is the most widely used definition, showed the lowest discriminative ability for clinically
significant nocturia.
Whereas the most discriminating models for clinically significant nocturia used NI as the definition
of NP, it is debatable whether NI is a definition of NP, or rather of nocturia. Based on the NI formula [3]
(i.e., the ratio between nightly voided volume and FBC), FBC is the factor that determines NP-risk.
Therefore, it may indicate a high risk of NP due to a small FBC. NI is, therefore, likely not to be specific
to NP, which means it is not appropriate as a definition of excess urine production at night (NP).
Instead, the NUPh parameter might be more appropriate and specific to NP. Being able to differentiate
those nocturia patients for whom NP is a contributing factor is important in understanding how to
manage the condition and reduce the bothersome symptom. Fulfilling a diagnostic criterion of NP
would require treatment with, e.g., an antidiuretic, whereas low FBC would more likely benefit from
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treatment with an anticholinergic or a beta-3 adrenergic agonist. We, therefore, suggest use of NUPh
as specific to NP. This measure has previously been shown to be valid in elderly males, but it has now
been shown to apply to the full age range of adult males and females in this independent dataset. Since
the aim of this analysis was to find a discriminative model for clinically significant nocturia, we have
determined that NUPh provides a reliable model when combined with FBC and sleep duration as
separate factors.
In the multivariate model, including demographic factors did not increase the predictability.
This simplified the model and the information needed, as input for this model is also easily accessible
for the clinician. The NUPh parameter also does not require information on daytime urinary volumes.
However, it is still clinically important to collect this information using the FVC so that 24 h polyuria,
not confined to the night time, can be identified if present, and dealt with appropriately before
considering treatment strategies for nocturia and nocturnal polyuria specifically. The NUPh model is,
therefore, a helpful diagnostic criterion in clinical practice. Our study was a post hoc analysis based on
individual data in a pooled analysis. Although the sample size was quite large, this may constitute a
bias in the study populations analyzed. However, there were similar trends in the individual studies
as in the pooled analysis. Despite some minor differences between females and males, the model was
applicable to both.
The population in this study was included based on a complaint of nocturia, i.e., the primary
selection criterion was related to feeling bothered by nocturnal voids, independent of the number of
voids. As a result, very few patients in the dataset had no nocturnal voids, even in the comparison
group with no/mild nocturia. It can be speculated that the contrast in nocturnal urine volume between
those with clinically significant nocturia and no/mild nocturia would become more explicit if more
patients with no nocturia were added to the comparison group. However, the current dataset is a
good representation of the clinical reality in that patients who seek help for nocturia experience the
symptom to some degree and it is the physician’s task to differentiate those with clinically significant
symptoms and the etiology of their condition.
It is also important to note that we excluded patients with chronic diseases associated with
nocturia, such as uncontrolled diabetes mellitus, uncontrolled hypertension, previous malignancies
and sleep apnea. The model is thus designed to apply to the specific subpopulation of nocturia
patients who have functional urological diseases. The model should, therefore, be utilized once other
underlying conditions and comorbidities—not relating to functional urology—have been excluded or
treated accordingly [16].
5. Conclusions
To our knowledge, this is the first time all published definitions of NP have been tested in a large
dataset of adult men and women with a complaint of nocturia.
All NP definitions (continuous and binary) showed significant associations with clinically
significant nocturia and no/mild nocturia, as demonstrated in the univariate analysis. Sleep duration,
bladder capacity, gender at birth and race also showed a significant association. However, multivariate
analyses showed that the association of gender and race to nocturia status was mediated by the
intake/output factors.
The multivariate analyses showed that the most discriminative definitions of NP were NI and
NUPh. The previously proposed binary NP definitions performed more poorly than the equivalent
continuous indices. However, these analyses also highlighted that NI was not specific to excess of
nightly urine production, as it also captured nocturia due to small FBC. In contrast, NUPh seemed to be
a definition of excess of nightly urine production alone, leading to good performance when combined
with bladder size and sleep duration as a marker for clinically significant nocturia. This confirms a
previously published finding in elderly males using the NUPh parameter, and extends its applicability
to females and a younger population.
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Therefore, we recommend using continuous NUPh (in the absence of 24 h polyuria), without
applying a threshold for disease, as specific to an excess of nightly urine production for a general
population that has a complaint of nocturia. This finding is important for the understanding of each
treatable contributing factor and, therefore, for the selection of effective treatment for nocturia.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/9/7/2262/s1,
Table S1: Significance level of univariate analysis of variables on a per patient basis.
Author Contributions: Conceptualization, T.O., M.J.D., J.V. and K.E.; Data curation, T.O., J.P. and P.G.;
Formal analysis, J.P. and P.G.; Funding acquisition, T.O.; Investigation, T.O.; Methodology, P.G. and K.E.;
Project administration, T.O.; Software, J.P. and P.G.; Supervision, T.O. and K.E.; Validation, T.O.; Writing–original
draft, T.O.; Writing–review & editing, J.P., P.G., M.J.D., J.V. and K.E. All authors have read and agreed to the
published version of the manuscript.
Funding: Authors have received funding for the statistical analysis from Ferring Pharmaceuticals.
Acknowledgments: The authors thanks Ferring Pharmaceuticals for access to data.
Conflicts of Interest: The authors declare no conflict of interest. The paper was reviewed by Ferring
Pharmaceuticals for correctness.
References
1. Bosch, J.L.; Weiss, J.P. The Prevalence and Causes of Nocturia. J. Urol. 2010, 184, 440–446. [CrossRef]
[PubMed]
2. Hafner, M.; Troxel, W.M.; Yerushalmi, E.; Fays, C.; Whitmore, M.; van Stolk, C. How Frequent Night-Time
Bathroom Visits Can Negatively Impact Sleep, Wellbeing and Productivity; Published as E-book by the RAND
Corporation; RAND Corporation: Santa Monica, CA, USA; Cambridge, UK, 2019; Available online:
https://www.rand.org/pubs/research_reports/RR3043.html (accessed on 20 November 2019).
3. Tikkinen, K.A.O.; Auvinen, A.; Johnson, T.M.; Weiss, J.P.; Keränen, T.; Tiitinen, A.; Polo, O.; Partinen, M.;
Tammela, T.L.J. A Systematic Evaluation of Factors Associated with Nocturia—The Population-based FINNO
Study. Am. J. Epidemiol. 2009, 170, 361–368. [CrossRef] [PubMed]
4. Brubaker, L.; Fitz Gerald, M.P. Nocturnal polyuria and nocturia relief in patients treated with solifenacin
for overactive bladder symptoms. Int. Urogynecol. J. Pelvic. Floor Dysfunct. 2007, 18, 737–741. [CrossRef]
[PubMed]
5. Rackley, R.; Weiss, J.P.; Rovner, R.S.; Wang, J.T.; Guan, Z. Nighttime dosing with tolterodine reduces overactive
bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Adult Urol. 2006, 67,
731–736. [CrossRef] [PubMed]
6. Kaplan, S.A.; Roehrborn, C.G.; Rovner, E.S.; Carlsson, M.; Bavendam, T.; Guan, Z. Tolterodine and tamsulosin
for treatment of men with lower urinary tract symptoms and overactive bladder: A randomized controlled
trial. JAMA 2006, 296, 2319–2328. [CrossRef] [PubMed]
7. Koseoglu, H.; Aslan, G.; Ozdemir, I.; Esen, A. Nocturnal polyuria in patients with lower urinary tract
symptoms and response to alpha-blocker therapy. Urology 2006, 67, 1188–1192. [CrossRef]
8. Weiss, J.P. Nocturia: Etiology and Consequence. Rev. Urol. 2012, 14, 48–55. [CrossRef]
9. Park, H.K.; Kim, H.G. Current evaluation and treatment of nocturia. Korean J. Urol. 2013, 54, 492–498.
[CrossRef]
10. Raskolnikov, D.; Friedman, F.M.; Etwaru, D.J.; Weiss, J.P. The evaluation and management of persistent
nocturia. Curr. Urol. Rep. 2014, 15, 439. [CrossRef]
11. Klingler, H.C.; Heidler, H.; Madersbacher, H.; Primus, G. Nocturia: An Austrian study on the multifactorial
etiology of this symptom. Neurourol. Urodyn. 2009, 28, 427–431. [CrossRef]
12. Abrams, P.; Cardozo, L.; Fall, M.; Griffiths, D.; Rosier, P.; Ulmsten, U.; Van Kerrebroeck, P.; Victor, A.;
Wein, A. The standardization of terminology of lower urinary tract function: Report from the Standardization
Sub-committee of the International Continence Society. Neurourol. Urodyn. 2002, 21, 167–178. [CrossRef]
[PubMed]
13. Hashim, H.; Blanker, M.; Drake, M.J.; Djurhuus, J.C.; Meijlink, J.; Morris, V.; Petros, P.; Wen, J.G.; Wein, A.
International Continence Society (ICS) report on the terminology for nocturia and nocturnal lower urinary
tract function. Neurourol. Urodyn. 2019, 38, 499–508. [CrossRef] [PubMed]
J. Clin. Med. 2020, 9, 2262 10 of 10
14. Bosch, J.R.; Everaert, K.; Weiss, J.P.; Hashim, H.; Rahnama’i, M.S.; Goessaert, A.S.; Aizen, J. Would a new
definition and classification of nocturia and nocturnal polyuria improve our management of patients? ICI-RS
2014. Neurourol. Urodyn. 2014, 35, 283–287. [CrossRef] [PubMed]
15. Olesen, T.K.; Denys, M.A.; Goessaert, A.S.; Bruneel, E.; Decalf, V.; Helleputte, T.; Paul, J.; Gramme, P.;
Everaert, K. Development of a multivariate prediction model for nocturia, based on urinary tract etiologies.
Int. J. Clin. Pract. 2019, e13306. [CrossRef] [PubMed]
16. Bower, W.F.; Rose, G.E.; Ervin, C.F.; Goldin, J.; Whishaw, D.M.; Khan, F. TANGO—A screening tool to identify
comorbidities on the causal pathway of nocturia. BJU Int. 2017, 119, 933–941. [CrossRef] [PubMed]
17. Blanker, M.H.; Bernsen, R.M.; Bosch, J.R.; Thomas, S.; Groeneveld, F.P.; Prins, A.; Bohnen, A.M. Relation
between nocturnal voiding frequency and nocturnal urine production in older men: A population-based
study. Urology 2002, 60, 612–616. [CrossRef]
18. Homma, Y.; Yamaguchi, O.; Kageyama, S.; Nishizawa, O.; Yoshida, M.; Kawabe, K. Nocturia in the adult:
Classification on the basis of largest voided volume and nocturnal urine production. J. Urol. 2000, 163,
777–781. [CrossRef]
19. Van Kerrebroeck, P.; Abrams, P.; Chaikin, D.; Donovan, J.; Fonda, D.; Jackson, S.; Jennum, P.; Johnson, T.;
Lose, G.; Mattiasson, A.; et al. The Standardisation of Terminology in Nocturia: Report from the
standardisation Sub-Committee of the ICS. Neurourol. Urodyn. 2002, 21, 179–183. [CrossRef]
20. Weiss, J.P.; Blaivas, J.G.; Stember, D.S.; Chaikin, D.C. Evaluation of the Etiology of Nocturia in Men:
The Nocturia and Nocturnal Bladder Capacity Indices. Neurourol. Urodyn. 1999, 18, 559–565. [CrossRef]
21. Goessaert, A.S.; Walle, J.V.; Bosch, R.; Hoebeke, P.; Everaert, K. Nocturnal Polyuria: Excess of Nocturnal
Urine Production, Excess of Definitions-Influence on Renal Function Profile. J. Urol. 2016, 195, 670–676.
[CrossRef]
22. Rembratt, A.; Norgaard, J.P.; Andersson, K.E. What is nocturnal polyuria? BJU Int. 2002, 90 (Suppl. S3),
18–20. [CrossRef]
23. Akiyama, T.; Hirayama, A.; Fujimoto, K.; Torimoto, K.; Yoshida, K.; Hirao, Y. Cutoff Value of Urinary
Arginine Vasopressin for Nocturnal Polyuria in Elderly Men. Urology 2007, 69, 98–102. [CrossRef]
24. Van Haarst, E.P.; Bosch, J.R. A Cutoff Value Based on Analysis of a Reference Population Decreases
Overestimation of the Prevalence of Nocturnal Polyuria. J. Urol. 2012, 188, 869–874. [CrossRef] [PubMed]
25. Van Doorn, B.; Blanker, M.H.; Kok, E.T.; Westers, P.; Bosch, J.R. Prevalence, Incidence, and Resolution of
Nocturnal Polyuria in a Longitudinal Community-based Study in Older Men: The Krimpen Study. Eur. Urol.
2013, 63, 542–547. [CrossRef] [PubMed]
26. Avulova, S.; Blanker, M.H.; van Doorn, B.; Weiss, J.P.; Bosch, J.R.; Tsui, J.F.; Khusid, J.A.; Golombos, D.;
Blaivas, J.G. Determinants of nocturia severity in men, derived from frequency–volume charts. Scand. J. Urol.
2014, 49, 185–188. [CrossRef]
27. Rembratt, A.; Norgaard, J.P.; Andersson, K.-E. Differences between nocturics and non-nocturics in voiding
patterns: An analysis of frequency-volume charts from community-dwelling elderly. BJU Int. 2002, 91, 45–50.
[CrossRef]
28. Bing, M.H.; Moller LAJennum, P.; Mortensen, S.; Lose, G. Pathophysiological Aspects of Nocturia in a Danish
Population of Men and Women Age 60 to 80 Years. J. Urol. 2007, 178, 552–557. [CrossRef] [PubMed]
29. Kirkland, J.L.; Lye, M.; Levy, D.W.; Banerjee, A.K. Patterns of urine flow and electrolyte excretion in healthy
elderly people. Br. Med. J. 1983, 287, 1665–1667. [CrossRef]
30. Udo, Y.; Nakao, M.; Honjo, H.; Ukimura, O.; Kawauchi, A.; Kitakoji, H.; Miki, T. Analysis of nocturia
with 24-h urine volume, nocturnal urine volume, nocturnal bladder capacity and length of sleep duration:
Concept for effective treatment modality. BJU Int. 2010, 107, 791–798. [CrossRef]
31. Benjamini, Y.; Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to
Multiple Testing. J. R. Stat. Soc. 1995, 57, 289–300. [CrossRef]
32. Nadeau, C.; Bengio, B. Papers Published at the Neural Information Processing Systems Conference ©
1987—2019 Neural Information Processing Systems (NIPS) Foundation, Inc. Available online: http:
//papers.nips.cc/paper/1661-inference-for-the-generalization-error.pdf (accessed on 20 November 2019).
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
